In patients with mantle cell lymphoma (MCL), outcomes are heterogeneous and the clinical significance of time of relapse following autologous hematopoietic cell transplantation (autoHCT) on overall survival (OS) is unknown. Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the results of an investigation using the CIBMTR database to evaluate the effect of post-autoHCT time to relapse on OS over time. Dr Riedell discusses that in MCL, early relapse following autoHCT defines a high-risk group with inferior post-relapse OS. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.